NASDAQ · MMED

MiniMed Group, Inc.

$16.83 +$0.50 (+3.06%) 1D Market open

Key Metrics

$4.59B
Market cap
P/E · TTM
$3.10B
Revenue · TTM
−$333.00M
Net income
EPS · TTM $-1.32
Dividend yield
Free cash flow −$420.00M
Beta · 1Y
EBITDA · TTM −$33.00M
Gross margin 54.2%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 3
    The stock moved +15.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 3
  • May 15
    From its Mar 6 high, the share price fell 42%.

    Peak close $18.49 on Mar 6; trough close $10.80 on May 15. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -42%
  • Mar 12
    The stock moved -8.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 12

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.59B
Enterprise value
Shares outstanding280.8M
52-wk range$10.65 – $20.48
Avg volume · 20D1.1M
Net cash
Book value / share$14.28
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About MiniMed Group, Inc.
IPO dateMar 6, 2026
Employees2800

Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.48
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 54.2%
Operating -6.1%
Net -10.7%
FCF -13.5%
ROE / ROIC -9.2% · -9.6%

Financial Health

Current ratio1.92
Quick ratio1.43
Debt / equity
Debt / EBITDA
Net cash
Working capital$646.00M

Cash Flow · TTM

Operating CF −$197.00M
Capex −$223.00M
Free cash flow −$420.00M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

3.4
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-01-23 · computed by TickerWolf from SEC filings